Juliana González-Sanmiguel

Ms. Juliana González-Sanmiguel

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2018 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
EFEduardo Javier Fernandez
Eduardo Javier Fernandez
FSFernando J. Sepúlveda
Fernando J. Sepúlveda
CPChristian Peters
Christian Peters
DBDenisse Bascuñán
Denisse Bascuñán
NRNicolás O. Riffo-Lepe
Nicolás O. Riffo-Lepe
LALuis G Aguayo
Luis G Aguayo
Background: The beta-amyloid peptide (Aβ) involved in Alzheimer’s disease (AD) has been described to associate/aggregate on the cell surface disrupting the membrane through pore formation and breakage. However, molecular determinants involved for this interaction (e.g., some physicochemical properties of the cell membrane) are largely unknown. Since cholesterol is an important molecule for membrane structure and fluidity, we examined the effect of varying cholesterol content with the association and membrane perforation by Aβ in cultured hippocampal neurons. Methods: To decrease or increase the levels of cholesterol in the membrane we used methyl-β-cyclodextrin (MβCD) and MβCD/cholesterol, respectively. We analyzed if membrane fluidity was affected using generalized polarization (GP) imaging and the fluorescent dye di-4-ANEPPDHQ. Additionally membrane association and perforation was assessed using immunocytochemistry and electrophysiological techniques, respectively. Results: The results showed that cholesterol removal decreased the macroscopic association of Aβ to neuronal membranes (fluorescent-puncta/20 μm: control = 18 ± 2 vs. MβCD = 10 ± 1, p < 0.05) and induced a facilitation of the membrane perforation by Aβ with respect to control cells (half-time for maximal charge transferred: control = 7.2 vs. MβCD = 4.4). Under this condition, we found an increase in membrane fluidity (46 ± 3.3% decrease in GP value, p < 0.001). On the contrary, increasing cholesterol levels incremented membrane rigidity (38 ± 2.7% increase in GP value, p < 0.001) and enhanced the association and clustering of Aβ (fluorescent-puncta/20 μm: control = 18 ± 2 vs. MβCD = 10 ± 1, p < 0.01), but inhibited membrane disruption. Conclusion: Our results strongly support the significance of plasma membrane organization in the toxic effects of Aβ in hippocampal neurons, since fluidity can regulate distribution and insertion of the Aβ peptide in the neuronal membrane.

13 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
JGJuliana González-Sanmiguel
Juliana González-Sanmiguel
CSChristina Schuh
Christina Schuh
CMCarola Muñoz-Montesino
Carola Muñoz-Montesino
PCPamina Contreras-Kallens
Pamina Contreras-Kallens
LALuis G Aguayo
Luis G Aguayo
SASebastian Aguayo
Sebastian Aguayo
Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Creutzfeldt–Jakob disease (CJD) are brain conditions affecting millions of people worldwide. These diseases are associated with the presence of amyloid-β (Aβ), alpha synuclein (α-Syn) and prion protein (PrP) depositions in the brain, respectively, which lead to synaptic disconnection and subsequent progressive neuronal death. Although considerable progress has been made in elucidating the pathogenesis of these diseases, the specific mechanisms of their origins remain largely unknown. A body of research suggests a potential association between host microbiota, neuroinflammation and dementia, either directly due to bacterial brain invasion because of barrier leakage and production of toxins and inflammation, or indirectly by modulating the immune response. In the present review, we focus on the emerging topics of neuroinflammation and the association between components of the human microbiota and the deposition of Aβ, α-Syn and PrP in the brain. Special focus is given to gut and oral bacteria and biofilms and to the potential mechanisms associating microbiome dysbiosis and toxin production with neurodegeneration. The roles of neuroinflammation, protein misfolding and cellular mediators in membrane damage and increased permeability are also discussed.

2 May 2017 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
RCRicardo Cabezas
Ricardo Cabezas
NVNelson E. Vega-Vela
Nelson E. Vega-Vela
JGJuliana González-Sanmiguel
Juliana González-Sanmiguel
JGJanneth González
Janneth González
PEPaula Esquinas
Paula Esquinas
GBGeorge E. Barreto
George E. Barreto

1 July 2020 in Neurobiology of Disease
Verified
Journal Article
Open access
CPChristian Peters
Christian Peters
DBDenisse Bascuñán
Denisse Bascuñán
CBCarlos Felipe Burgos
Carlos Felipe Burgos
CBCatalina Bobadilla
Catalina Bobadilla
JGJuliana González-Sanmiguel
Juliana González-Sanmiguel
LALuis G Aguayo
Luis G Aguayo
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in elderly people. Existent therapies are directed at alleviating some symptoms, but are not effective in altering the course of the disease. Based on our previous study that showed that an Aβ-interacting small peptide protected against the toxic effects of amyloid-beta peptide (Aβ), we carried out an array of in silico, in vitro, and in vivo assays to identify a molecule having neuroprotective properties. In silico studies showed that the molecule, referred to as M30 (2-Octahydroisoquinolin-2(1H)-ylethanamine), was able to interact with the Aβ peptide. Additionally, in vitro assays showed that M30 blocked Aβ aggregation, association to the plasma membrane, synaptotoxicity, intracellular calcium, and cellular toxicity, while in vivo experiments demonstrated that M30 induced a neuroprotective effect by decreasing the toxicity of Aβ in the dentate gyrus of the hippocampus and improving the alteration in spatial memory in behavior assays. Therefore, we propose that this new small molecule could be a useful candidate for the additional development of a treatment against AD since it appears to block multiple steps in the amyloid cascade. Overall, since there are no drugs that effectively block the progression of AD, this approach represents an innovative strategy. Currently, there is no effective treatment for AD and the expectations to develop an effective therapy are low. Using in silico, in vitro, and in vivo experiments, we identified a new compound that is able to inhibit Aβ-induced neurotoxicity, specifically aggregation, association to neurons, synaptic toxicity, calcium dyshomeostasis and memory impairment induced by Aβ. Because Aβ toxicity is central to AD progression, the inhibition mediated by this new molecule might be useful as a therapeutic tool.

4 September 2020 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
JGJuliana González-Sanmiguel
Juliana González-Sanmiguel
CBCarlos Felipe Burgos
Carlos Felipe Burgos
DBDenisse Bascuñán
Denisse Bascuñán
EFEduardo J. Fernández-Pérez
Eduardo J. Fernández-Pérez
NRNicolás Riffo-Lepe
Nicolás Riffo-Lepe
LALuis G Aguayo
Luis G Aguayo

24 September 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PSPaulina Saavedra-Sieyes
Paulina Saavedra-Sieyes
IMIsaías Meza
Isaías Meza
NRNicolas Riffo-Lepe
Nicolas Riffo-Lepe
LMLoreto San Martin
Loreto San Martin
JGJuliana González-Sanmiguel
Juliana González-Sanmiguel
LALuis G Aguayo
Luis G Aguayo
Alzheimer's disease is a neurodegenerative disease. Recently, alterations in the mesolimbic system have been described, especially in the nucleus accumbens (nAc). We found that intracellular accumulation of Aβ was higher in neurons of the APP/PS1 mice at 10 and 15 days in vitro . At 15 days in vitro (DIV), APP/PS1 accumbal neurons showed alterations in synaptic transmission and neuronal excitability. Specifically, there was an increase in AMPAergic synaptic currents, which was sensitive to the application of NASPM, suggesting a critical role for calcium-permeable AMPA receptors (CP-AMPARs). Our study indicates that this neuronal culture model accurately replicates alterations in the early stages of AD.